KMDA.TA - Kamada Ltd.
| Previous Close | 2,550.00 |
| Open | 2,550.00 |
| Bid | 2,479.00 x 346500 |
| Ask | 2,481.00 x 57900 |
| Day's Range | 2,478.00 - 2,550.00 |
| 52 Week Range | 1,732.00 - 2,729.00 |
| Volume | 28,702 |
| Avg. Volume | 80,177 |
| Market Cap | 1B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 2,837.53 |
| EPS (TTM) | 0.87 |
| Earnings Date | Feb 10, 2020 - Feb 14, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- GlobeNewswire
Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product
Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a U.S. Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product. Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.
- Thomson Reuters StreetEvents
Edited Transcript of KMDA.TA earnings conference call or presentation 13-Nov-19 1:30pm GMT
Q3 2019 Kamada Ltd Earnings Call
- GlobeNewswire
Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel
Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, upon receipt of regulatory approval from the Israeli Ministry of Health (IMOH). Kamada leverages its expertise and presence in the Israeli market to distribute, in Israel, more than 20 products that are manufactured by third parties.
- Insider Monkey
Did Hedge Funds Drop The Ball On Kamada Ltd (KMDA) ?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]
- GlobeNewswire
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2019
Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective.
- GlobeNewswire
Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and nine months ended September 30, 2019, prior to the open of the U.S. financial markets on Wednesday, November 13, 2019. Kamada management will host an investment community conference call on Wednesday, November 13 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1 809 406 247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13695272.
- GlobeNewswire
Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin ) in Human Vaccines & Immunotherapeutics Medical Journal
TASE: KMDA) and Kedrion Biopharma two leading plasma-derived protein therapeutics companies, announced today that the results of their registration study for KEDRAB® [Rabies Immune Globulin (Human)] were published in Human Vaccines & Immunotherapeutics, a peer-reviewed medical journal covering research into vaccines and immunotherapeutics in humans.
- GlobeNewswire
Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference
REHOVOT, Israel, Sept. 24, 2019 -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive.
- GlobeNewswire
Kamada Announces Extension of GLASSIA® Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current.
- Thomson Reuters StreetEvents
Edited Transcript of KMDA.TA earnings conference call or presentation 6-Aug-19 12:30pm GMT
Q2 2019 Kamada Ltd Earnings Call
- GlobeNewswire
Kamada Reports Discussions with Takeda Regarding a Potential Extension of the Period for the Transition of GLASSIA Manufacturing to Takeda
TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda to extend the period prior to transitioning the manufacture of GLASSIA, Kamada’s proprietary product for the treatment of Alpha-1 Antitrypsin Deficiency, to Takeda. Kamada will provide additional information regarding the discussions, if appropriate, at a later date. As background, Kamada has supplied GLASSIA to Takeda, or its predecessors, since 2010. The GLASSIA supply agreement with Takeda currently extends through the end of 2020, followed by an expected transition of GLASSIA manufacturing to Takeda. While the transition of GLASSIA manufacturing to Takeda after 2020 will result in a significant reduction of Kamada’s revenues, based on the current terms of the supply agreement, Kamada would be entitled to future royalty payments until 2040.
Motley FoolKamada Ltd. (KMDA) Q2 2019 Earnings Call Transcript
KMDA earnings call for the period ending June 30, 2019.
- GlobeNewswire
Kamada Reports Financial Results for Second Quarter and First Six Months of 2019
Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-YearTotal Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase.
- GlobeNewswire
Kamada to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6
REHOVOT, Israel, July 31, 2019 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
Motley FoolKamada Ltd. (KMDA) Q1 2019 Earnings Call Transcript
KMDA earnings call for the period ending March 31, 2019.
- Associated Press
Kamada: 1Q Earnings Snapshot
The Rehovot, Israel-based company said it had net income of 12 cents per share. Earnings, adjusted for stock option expense, came to 13 cents per share. The biopharmaceutical posted revenue of $26.8 million ...
- GlobeNewswire
Kamada Reports Financial Results for First Quarter of 2019
Total Revenues for Q1 2019 were $26.8 Million, up 54% over Q1 2018Q1 2019 Proprietary Products Revenues up 67% Year-over-Year Gross Profit for Q1 2019 Grew 59%.
- Benzinga
A Preview Of Kamada's Q1 Earnings
Kamada Ltd. (NASDAQ: KMDA ) releases its next round of earnings this Tuesday, May 14. Here's Benzinga's essential guide to Kamada's first-quarter earnings report. Earnings and Revenue Analysts covering ...
- GlobeNewswire
Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
REHOVOT, Israel, May 07, 2019 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
- GlobeNewswire
Kamada announces FDA acceptance of Inhaled AAT program path forward
REHOVOT, Israel, April 16, 2019 -- Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food.
- GlobeNewswire
Kamada Awarded the Israeli Outstanding Exporter Award for 2017
For fiscal 2017, Kamada's total revenues were $102.8 Million, an increase of more than 33% compared to 2016. REHOVOT, Israel, March 14, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it has been awarded the Israeli Outstanding Exporter Award for 2017 by the Foreign Trade Department of the Israeli Ministry of Economy and Industry.
- GlobeNewswire
Kamada Files Annual Report for the Year Ended December 31, 2018
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”). The annual report, which contains the Company’s audited consolidated financial statements, can be accessed via the SEC’s website at http://www.sec.gov/ as well as under the SEC Filings section on the Company’s investor relations website at http://www.kamada.com/reports.php.
- Associated Press
Kamada: 4Q Earnings Snapshot
On a per-share basis, the Rehovot, Israel-based company said it had profit of 44 cents. Earnings, adjusted for stock option expense, were 45 cents per share. The biopharmaceutical posted revenue of $48.2 ...
- GlobeNewswire
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
Total Revenues for Fiscal 2018 were $114.5 Million, up 11% Over Fiscal 2017; In-line with Recently Provided 2018 Expected Revenues of $113 Million and $115 Million Full-Year.
- GlobeNewswire
Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test. The study is being conducted at the Rabin Medical Center - Beilinson Hospital in Israel, under the leadership of Professor Mordechai R. Kramer, M.D., Director of the Institute of Pulmonary Medicine at the Center. The study is being conducted in collaboration with Shire plc, now owned by Takeda.
